Cancer Awareness Seminar Series

Cancer Awareness Seminar Series

Smoking Cessation Tips and Your Options for Lung Cancer Screening

The Baptist Cancer Center and Vanderbilt-Ingram Cancer Center invite you to a free educational seminar featuring two of our nationally recognized oncologists.

All seminars will be held at the Baptist Memorial Hospital - Memphis Education Center
6027 Walnut Grove Rd. Medical Plaza 2, First Floor (Classrooms BEC 3-5).

Complimentary parking is available.

Pre-registration is required.
You may sign up here to receive notices of upcoming seminars with links to pre-registration pages.

Agenda

6:00 – 6:15 pm
- Refreshments and seating
6:15 – 6:45 pm
- Dr. Donald Gravenor
6:45 – 7:15 pm
- Dr. Michael Neuss
7:15 – 7:30 pm
- Q & A

About the Speakers

Speaker photo

Raymond Uyiosa Osarogiagbon, MD, FACP

Dr. Raymond Uyiosa Osarogiagbon is a graduate of the University of Ibadan, Nigeria, and completed his internship at University College Hospital, also in Ibadan. Dr. Osarogiagbon was a member of the Nigerian National Youth Service Corps before going to Texas Tech University Health Sciences Center in Amarillo, Texas to complete an internal medicine internship and residency, ultimately serving as chief resident and winning the "Outstanding Resident of the Year" award. His next stop was Minneapolis, where Dr. Osarogiagbon did a fellowship in hematology/oncology. His numerous accolades include being named to Memphis Magazine's "Top Doctors" list from 2008 to 2013 and receiving a "Louise Evans Bruce Award" from Texas Tech University for “continued and invaluable support of the mission and vision of the Texas Tech University Health Sciences Center at Amarillo Medical School."

He has served as Director of the Multidisciplinary Thoracic Oncology Program at Boston Baskin Cancer Foundation since September 2011. Previously, Dr. Osarogiagbon served as Director of the University of Tennessee Hematology/Medical Oncology Fellowship Training Program.

He is a Diplomat of the American Board of Internal Medicine, a Fellow of the American College of Physicians and a member of several other professional societies. In the summer of 2012, Dr. Osarogiagbon won a $3 million grant from the National Cancer Institute to study lung cancer treatment with an already proven testing process he helped developed here in Memphis.

Speaker photo

Pierre P. Massion, MD

Dr. Pierre Massion is Ingram Professor of Cancer Research, Professor of Medicine in the Division of Allergy, Pulmonary and Critical Care Medicine and Professor of Cancer Biology at Vanderbilt Medical Center. Dr. Massion was recently named Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center.

His laboratory research focuses on the areas of airway cancer and pre-invasive cancer cell biology, the field of cancerization, biomarker development and validation for the early detection of lung cancer, and chemopreventive strategies for lung cancer. He is the director of an Early Detection Research Network (EDRN) Clinical Validation Center and the Principal Investigator of the Nashville Lung Cancer Screening Trial. He is the Chair of the Lung Cancer Cooperative group in the EDRN and the Chair of the Scientific Advisory Board of the largest non-profit lung cancer foundation LUNGevity. He is a contributing member to the National Comprehensive Cancer Network related Non-Small Cell Lung Cancer Guidelines committee. He is currently funded from the National Cancer Institute, the Department of Defense and the Department of Veterans Affairs in support of his research initiatives.

Dr. Massion is committed to pursuing innovative methods to deepen the knowledge of lung cancer development and early detection of lung cancer. He is interested in pre-invasive lung lesions and their predictive value for lung cancer development and, in particular, studies the in vivo model of lung tumorigenesis. He applies a series of genomic and proteomic new technologies to biological specimen including sputum, serum, and tissue biopsies to address questions related to the identification and validation of molecular determinants of disease progression, diagnosis and prognosis.